Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Vanguard Total Stock Market Index Fund ETF trades at $376 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 203.4× Repligen Corporation Common Stock's market cap, and Vanguard Total Stock Market Index Fund ETF is more actively traded (3,256,421 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| RGEN | VTI | |
|---|---|---|
Market Cap | $11.31B | $2.30T |
Volume | 1,216,919 | 3,256,421 |
Sector | Health | — |
52-Week High | $194.57 | $384.30 |
52-Week Low | $102.87 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VTI trades at $381.32, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers broad U.S. equity exposure, though key financial ratios are not provided in the data. Recent news highlights its appeal for long-term investors seeking diversification and low-cost market access.
The outlook remains positive given strong technical momentum and media optimism, but risks include market concentration in top holdings and broader economic volatility. Investors benefit from VTI's extensive diversification, yet should monitor allocation weights and macroeconomic trends for potential impacts on returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
